Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
13.88 EUR | -1.70% | +0.73% | +41.34% |
Apr. 11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
Apr. 08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.34% | 947M | |
-1.82% | 41.35B | |
+42.15% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- Abivax : Stops Anti-Inflammatory Drug Study in High-Risk COVID-19 Patients Due to Ineffectiveness